Skip to content Skip to footer

Up to 1 in 10 of all cancers are inherited.
STOP PAYING FOR
LATE DIAGNOSIS
dna

Inherited cancer risk is a global working-age blind spot—devastating families, disrupting businesses, and costing healthcare funders and insurers £ billions

Early diagnosis transforms outcomes. Yet > 90% of high risk carriers are unaware and unprotected

What we do

Who is KINsight for?

Health Systems

Drive Population Scale Prevention-Led Healthcare – Systematically identify and reduce inherited cancer risk at population level.
Read More

Insurers

Reduce already provisioned oncology claims volatility while improving long-term portfolio BCR.
Read More

Oncology Centres

Enable earlier identification and MDT-led management of inherited cancer risk, reducing late-stage complexity.
Read More

Corporate EB Leaders

Protect Your Workforce – Reduce preventable high-cost cancer across your population.
Read More

Private Hospitals

Strengthen Oncology Pathways – Identify high-risk patients earlier and enhance structured care delivery.
Read More

Individuals & Families

Understand Your Family’s Risk – Gain clarity on your inherited cancer risk before a crisis occurs.
Read More
What we do

Powering Health Ecosystems with AI Insight

About Us

A Global Platform for Health Intelligence

ESH AI Healthcare is a subsidiary of ESH Solutions Ltd, Jersey, operating as a dedicated division focused on precision, preventive, and protective healthcare solutions.

Our approach moves healthcare beyond treatment toward early risk detection, personalized health intelligence, and continuous protection, enabling scalable impact across geographies and populations. Designed as a global health intelligence platform, ESH AI Healthcare bridges technology, data, and human outcomes to shape the future of proactive healthcare.

AI Analytics

Predictive models enabling smarter, earlier health decisions

Genetic Intelligence

Personalized risk insights based on genetic profiling

Digital Health Insights

Continuous data translating health signals into action

Patient Advocacy Organisations

We engage with patient advocacy organisations to ensure lived experience continually informs our approach.
Collaboration with national inherited cancer advocacy groups ensures responsible deployment, transparent engagement, and alignment between genomic risk infrastructure and high-risk family needs.

Getting Confirmation

The KINsight platform does not give a medical diagnosis. If you have completed your Genetic Family Tree and been recommended for referral to a genetic service we advise strongly that you take the recommendation and discuss directly with your GP or Primary Care Physician.

The only way to confirm if an individual is a carrier of an inherited genetic risk of cancer is via genetic germline testing and this can be arranged directly with…….

Economic Shift Proof

Large-format measurable population impact metrics.
VIEW FULL IMPACT MODEL

Impact Model Preview

Model your population in under 60 seconds.
LAUNCH IMPACT MODEL
Home contact
Contact Us

Have questions?
Get in touch!

    From our blog

    News and insights

    Top 5 challenges in modern drug discovery
    Sed ut perspiciatis unde omnis iste natus ut perspic iatis…
    From concept to cure: drug discovery steps
    Sed ut perspiciatis unde omnis iste natus ut perspic iatis…
    Emerging trends in targeted drug discovery
    Sed ut perspiciatis unde omnis iste natus ut perspic iatis…
    Receive News

    Subscribe for the Updates!

    Receive News

    Subscribe for the Updates!